
Sarepta Therapeutics, Inc.
SRPTHealthcare|Biotechnology|US
$17.82
+0.25 (+1.42%)
Tangible Book / Share
$14.15
Graham Number
$6.73
Cash / Share
$8.30
Financials
Financial Snapshot
Market Cap
$1.88B
Enterprise Value
$2.46B
Revenue (TTM)
$1.96B
Net Income (TTM)
$14.8M
Cash & Investments
$878.8M
Net Cash
-$174.3M
Free Cash Flow (TTM)
-$31.6M
Operating CF (TTM)
-$17.1M
Debt/Equity
0.69
Cash Runway & Burn Rate
Cash on Hand
$878.8M
Quarterly Burn
$4.3M
Monthly Burn
$1.4M
Est. Runway
~205.3 quarters
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $317.8M | $1.08B | $1.17B | $1.12B | $1.94B | $2.12B | $1.99B | $1.68B | $1.35B | $939.6M | $878.8M | |
| Operating Cash Flow | -$245.8M | -$232.0M | -$388.7M | -$456.5M | $107.5M | -$443.2M | -$325.3M | -$501.0M | -$205.8M | -$205.5M | -$17.1M | |
| Free Cash Flow | -$252.7M | -$253.2M | -$453.0M | -$516.1M | $25.3M | -$481.7M | -$357.6M | -$588.3M | -$352.7M | -$307.5M | -$31.6M | |
| Capital Expenditure | -$6.9M | -$21.2M | -$64.3M | -$59.6M | -$82.2M | -$38.5M | -$32.3M | -$87.3M | -$147.0M | -$102.0M | -$14.5M | |
| Financing Cash Flow | $378.1M | $888.1M | $530.1M | $642.6M | $682.3M | $561.6M | $232.5M | $125.0M | $124.8M | -$168.3M | -$38.7M |
R&D Spending
R&D (TTM)
$653.1M
R&D Intensity
33.4%
R&D Growth vs Prior
-57.1%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.4M | $154.6M | $301.0M | $380.8M | $540.1M | $701.9M | $933.0M | $1.24B | $1.90B | $2.20B | $1.96B | |
| R&D Expense | $188.3M | $166.7M | $401.8M | $560.9M | $722.3M | $771.2M | $877.1M | $877.4M | $804.5M | $1.52B | $653.1M | |
| R&D % of Revenue | 3473.0% | 107.8% | 133.5% | 147.3% | 133.7% | 109.9% | 94.0% | 70.6% | 42.3% | 69.2% | 33.4% | |
| SG&A | $83.7M | $122.7M | $207.8M | $284.8M | $317.9M | $282.7M | $451.4M | $481.9M | $557.9M | $478.9M | $463.5M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.4M | $154.6M | $301.0M | $380.8M | $540.1M | $701.9M | $933.0M | $1.24B | $1.90B | $2.20B | $1.96B | |
| Cost of Revenue | $130.0K | $7.4M | $34.2M | $56.6M | $63.4M | $97.0M | $140.0M | $150.3M | $319.1M | $881.5M | $856.0M | |
| Gross Profit | $5.3M | $147.2M | $266.8M | $324.2M | $476.7M | $604.8M | $793.0M | $1.09B | $1.58B | $1.32B | $1.10B | |
| R&D | $188.3M | $166.7M | $401.8M | $560.9M | $722.3M | $771.2M | $877.1M | $877.4M | $804.5M | $1.52B | $653.1M | |
| SG&A | $83.7M | $122.7M | $207.8M | $284.8M | $317.9M | $282.7M | $451.4M | $481.9M | $557.9M | $478.9M | $463.5M | |
| Operating Income | -$266.7M | -$171.6M | -$343.6M | -$705.6M | -$564.2M | -$459.7M | -$536.2M | -$267.8M | $218.1M | -$657.8M | -$48.9M | |
| Interest Expense | $1.9M | $5.8M | $33.7M | $30.7M | $59.9M | $63.5M | $53.2M | $22.0M | $18.4M | $9.7M | $72.4M | |
| Pretax Income | -$267.3M | -$48.6M | -$362.6M | -$713.9M | -$553.1M | -$418.9M | -$690.0M | -$520.1M | $260.8M | -$702.2M | $37.4M | |
| Net Income | -$267.3M | -$50.7M | -$361.9M | -$715.1M | -$554.1M | -$418.8M | -$703.5M | -$536.0M | $235.2M | -$713.4M | $14.8M | |
| EPS (Diluted) | -5.49 | -0.86 | -5.46 | -9.71 | -7.11 | -5.15 | -8.03 | -5.80 | 2.34 | -7.13 | -1.37 | |
| EBITDA | -$261.1M | -$34.8M | -$316.7M | -$658.7M | -$453.4M | -$317.4M | -$594.9M | -$453.7M | $316.9M | -$648.0M | $155.2M | |
| Shares Out. (M) | 48.70 | 58.82 | 66.25 | 73.61 | 77.96 | 81.26 | 87.56 | 92.40 | 107.88 | 104.79 | 105.93 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $122.4M | $599.7M | $370.8M | $835.1M | $1.50B | $2.12B | $966.8M | $428.4M | $1.10B | $801.3M | $472.8M | |
| Short-Term Investments | $195.4M | $479.4M | $803.1M | $289.7M | $435.9M | $0.00 | $1.02B | $1.25B | $251.8M | $138.4M | $406.0M | |
| Total Current Assets | $373.5M | $1.23B | $1.43B | $1.47B | $2.49B | $2.60B | $2.56B | $2.58B | $3.07B | $2.54B | $2.27B | |
| Total Assets | $424.1M | $1.31B | $1.64B | $1.82B | $2.98B | $3.15B | $3.13B | $3.26B | $3.96B | $3.35B | $3.17B | |
| Total Current Liabilities | $75.4M | $88.3M | $173.7M | $264.8M | $416.0M | $452.7M | $619.6M | $653.7M | $731.7M | $1.10B | $656.4M | |
| Long-Term Debt | $6.0M | $424.9M | $420.6M | $681.9M | $992.5M | $1.10B | $1.54B | $1.13B | $1.14B | $829.0M | $699.4M | |
| Total Liabilities | $87.4M | $518.7M | $609.8M | $1.00B | $2.22B | $2.22B | $2.74B | $2.41B | $2.44B | $2.21B | $1.64B | |
| Stockholders' Equity | $336.7M | $789.2M | $1.03B | $818.2M | $761.8M | $928.0M | $384.9M | $859.3M | $1.53B | $1.14B | $1.53B | |
| Retained Earnings | -$1.17B | -$1.22B | -$1.58B | -$2.29B | -$2.85B | -$3.21B | -$3.91B | -$4.45B | -$4.21B | -$4.88B | -$4.58B |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$245.8M | -$232.0M | -$388.7M | -$456.5M | $107.5M | -$443.2M | -$325.3M | -$501.0M | -$205.8M | -$205.5M | -$17.1M | |
| Capital Expenditure | -$6.9M | -$21.2M | -$64.3M | -$59.6M | -$82.2M | -$38.5M | -$32.3M | -$87.3M | -$147.0M | -$102.0M | -$14.5M | |
| Free Cash Flow | -$252.7M | -$253.2M | -$453.0M | -$516.1M | $25.3M | -$481.7M | -$357.6M | -$588.3M | -$352.7M | -$307.5M | -$31.6M | |
| Investing Cash Flow | -$90.2M | -$178.8M | -$370.5M | $286.7M | -$121.7M | $495.4M | -$1.05B | -$165.8M | $755.6M | $69.6M | -$424.3M | |
| Financing Cash Flow | $378.1M | $888.1M | $530.1M | $642.6M | $682.3M | $561.6M | $232.5M | $125.0M | $124.8M | -$168.3M | -$38.7M | |
| Issuance of Stock | $364.8M | $354.0M | $513.4M | $365.4M | $312.1M | $548.5M | $0.00 | $0.00 | $0.00 | $36.3M | $680.0K | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$25.0M | $0.00 | |
| Net Debt Issuance | -$7.6M | $585.0M | -$33.5M | $245.6M | $291.1M | $0.00 | $304.2M | $0.00 | -$68.0K | -$162.6M | -$35.1M | |
| Stock Based Comp. | $30.0M | $30.5M | $50.1M | $78.6M | $108.1M | $113.9M | $233.0M | $182.5M | $184.3M | $123.4M | $140.0M | |
| Net Change in Cash | $42.1M | $477.3M | -$229.0M | $472.8M | $668.1M | $613.8M | -$1.14B | -$541.8M | $674.6M | -$304.2M | -$480.1M |
Dilution Tracker
Shares outstanding grew 34.4% over 5 years — significant dilution
Shares Outstanding
106M
5-Year Share Growth
+34.4%
Stock Issuance (TTM)
$680.0K
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 48.70 | 58.82 | 66.25 | 73.61 | 77.96 | 81.26 | 87.56 | 92.40 | 107.88 | 104.79 | 105.93 | |
| Change vs Prior % | — | 20.8% | 12.6% | 11.1% | 5.9% | 4.2% | 7.7% | 5.5% | 16.8% | -2.9% | 1.1% | |
| Stock Issuance | $364.8M | $354.0M | $513.4M | $365.4M | $312.1M | $548.5M | $0.00 | $0.00 | $0.00 | $36.3M | $680.0K | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$25.0M | $0.00 | |
| Stock Based Comp. | $30.0M | $30.5M | $50.1M | $78.6M | $108.1M | $113.9M | $233.0M | $182.5M | $184.3M | $123.4M | $140.0M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 97.6% | 95.2% | 88.6% | 85.1% | 88.3% | 86.2% | 85.0% | 87.9% | 83.2% | 59.9% | 56.2% | |
| Operating Margin % | -4920.3% | -111.0% | -114.1% | -185.3% | -104.5% | -65.5% | -57.5% | -21.5% | 11.5% | -29.9% | -2.5% | |
| Net Margin % | -4930.2% | -32.8% | -120.2% | -187.8% | -102.6% | -59.7% | -75.4% | -43.1% | 12.4% | -32.5% | 0.8% | |
| EBITDA Margin % | -4816.8% | -22.5% | -105.2% | -173.0% | -83.9% | -45.2% | -63.8% | -36.5% | 16.7% | -29.5% | 7.9% | |
| FCF Margin % | -4661.2% | -163.8% | -150.5% | -135.5% | 4.7% | -68.6% | -38.3% | -47.3% | -18.5% | -14.0% | -1.6% | |
| ROE % | -79.4% | -6.4% | -35.1% | -87.4% | -72.7% | -45.1% | -182.7% | -62.4% | 15.4% | -62.5% | 1.0% | |
| ROA % | -63.0% | -3.9% | -22.0% | -39.2% | -18.6% | -13.3% | -22.5% | -16.4% | 5.9% | -21.3% | 0.5% | |
| ROIC % | -74.3% | -14.0% | -23.4% | -45.1% | -21.8% | -17.0% | -21.2% | -9.8% | 6.1% | -29.0% | -0.7% | |
| R&D / Revenue % | 3473.0% | 107.8% | 133.5% | 147.3% | 133.7% | 109.9% | 94.0% | 70.6% | 42.3% | 69.2% | 33.4% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 332.6% | 2751.6% | 94.7% | 26.5% | 41.8% | 30.0% | 32.9% | 33.3% | 53.0% | 15.6% | |
| Gross Profit | 103.7% | 2682.7% | 81.2% | 21.5% | 47.0% | 26.9% | 31.1% | 37.8% | 44.8% | -16.8% | |
| Operating Income | -21.1% | 35.7% | -100.2% | -105.3% | 20.0% | 18.5% | -16.6% | 50.1% | 181.4% | -401.6% | |
| Net Income | -21.5% | 81.0% | -614.0% | -97.6% | 22.5% | 24.4% | -68.0% | 23.8% | 143.9% | -403.3% | |
| EPS (Diluted) | -5.6% | 84.3% | -534.9% | -77.8% | 26.8% | 27.6% | -55.9% | 27.8% | 140.3% | -404.7% | |
| Operating Cash Flow | -64.5% | 5.6% | -67.5% | -17.4% | 123.5% | -512.4% | 26.6% | -54.0% | 58.9% | 0.1% | |
| Free Cash Flow | -63.8% | -0.2% | -78.9% | -13.9% | 104.9% | -2006.5% | 25.8% | -64.5% | 40.0% | 12.8% | |
| R&D Expense | 28.6% | -11.5% | 141.0% | 39.6% | 28.8% | 6.8% | 13.7% | 0.0% | -8.3% | 89.2% | |
| SG&A Expense | 11.6% | 46.5% | 69.3% | 37.1% | 11.6% | -11.1% | 59.7% | 6.7% | 15.8% | -14.1% | |
| Total Assets | 54.9% | 208.4% | 25.5% | 11.0% | 63.7% | 5.5% | -0.6% | 4.4% | 21.4% | -15.5% | |
| Book Value / Share | 53.7% | 94.0% | 16.1% | -28.7% | -12.1% | 16.9% | -61.5% | 111.5% | 72.8% | -32.3% | |
| Debt | -31.0% | 2569.0% | -2.4% | 75.4% | 48.3% | 5.5% | 40.2% | -13.6% | -3.8% | -22.6% | |
| Diluted Shares | 15.2% | 20.8% | 12.6% | 11.1% | 5.9% | 4.2% | 7.7% | 5.5% | 16.8% | -2.9% |
Valuation
P/E (TTM)198.00
P/S0.96
10Y Low / Med / High1.03 / 21.17 / 246.33
P/B1.23
10Y Low / Med / High1.98 / 7.89 / 29.47
EV/EBITDA15.87
EV/Revenue1.26
10Y Low / Med / High1.13 / 20.08 / 226.73
P/FCFAt Loss
Intrinsic Value Models (per share)
Tangible Book / Share
$14.15
Net Current Assets / Share
$6.02
Graham Number
$6.73
Cash / Share
$8.30
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -5.00 | -64.70 | -19.99 | -13.29 | -23.98 | -17.49 | -16.14 | -16.63 | 49.23 | -3.02 | 198.00 | |
| P/S Ratio | 246.33 | 21.17 | 24.02 | 24.94 | 24.61 | 10.43 | 12.16 | 7.17 | 6.08 | 1.03 | 0.96 | |
| P/B Ratio | 3.97 | 4.15 | 7.00 | 11.61 | 17.45 | 7.89 | 29.47 | 10.37 | 7.57 | 1.98 | 1.23 | |
| EV/EBITDA | -4.71 | -89.31 | -22.99 | -14.27 | -28.41 | -20.02 | -20.17 | -21.77 | 37.24 | -3.85 | 15.87 | |
| EV/Revenue | 226.73 | 20.08 | 24.18 | 24.69 | 23.85 | 9.05 | 12.86 | 7.95 | 6.20 | 1.13 | 1.26 |
Analyst Estimates & Quality
Altman Z-Score
0.02
Distress
Piotroski F-Score
4
Moderate
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $1.84B | $1.41B | $1.35B |
| Net Income | $335.7M | $40.6M | -$38.6M |
| EPS | $3.08 | $0.34 | $-0.03 |
| # Analysts (EPS) | 11 | 11 | 11 |
Revenue Segments
By Geography
| Segment | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Non-US | $96.7M | — | — | $165.2M |
| UNITED STATES | $747.1M | $797.9M | $820.8M | $898.7M |
| Rest of World | — | $146.6M | $150.2M | — |